Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer

Solid Tumors Clinical Trial

— STMN1-LP  

Official title:

Phase I Trial of Intratumoral Bi-functional shRNA Stathmin 1-knockdown Lipoplex in Patients With Advanced and/or Metastatic Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01505153
• Other study ID #: CL-PTL 103
• Status: Completed
• Phase: Phase 1
• First received: January 4, 2012
• Last updated: February 16, 2018
• Start date: February 2012
• Est. completion date: April 13, 2017

Study information

• Verified date: February 2018
• Source: Gradalis, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection. Patients with superficially accessible advanced cancer following prior therapies will be entered into the study following a modified dose escalation design based on the demonstrated safety of our previous clinical experience (BB-IND 13744) with the same liposome and vector DNA backbone expressing a different transgene (of which doses up to 7 mg DNA IV/single dose have been administered). Patients will accrue in 4-patient escalation cohorts using a modified Fibronacci escalation schema (100%-50%-33%-33%) at a starting intratumoral dose of 0.010 mg/kg of DNA through a dose of 0.053 mg/kg DNA intratumoral / single dose. Should a single, but not more than two (2), ≥ Grade 3 Dose Limiting Toxicity (DLT) occur in any cohort, following mandated review (see below) an additional two (2) patients will be accrued at that dose (total of six). If more than one ≥ Grade 3 toxicity occurs in any cohort, the preceding dose cohort will be expanded to six (from four) and if < 2/6 patients experience ≥ Grade 3 toxicity, that dose will be the Phase II recommended dose. Should no ≥ Grade 3 toxicity occur in any cohort (other than Grade 3 local injection site reaction), an additional two (2) patients will be treated at 0.053 mg/kg DNA intratumoral / single dose.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: April 13, 2017
• Est. primary completion date: March 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically confirmed advanced and/or metastatic cancer, and, if limited to a single lesion, not considered a candidate for curative surgery or radiation therapy).

2. Biopsy accessible lesion.

3. Per cohort dose/volume, the volume of the lesion to be injected must be 3x volume of the injectate.

4. Subjects that have completed all acceptable therapies with curative potential that are the current standard of care for their respective diseases.

5. Recovered from all toxicities (= Grade 1) related to prior therapies except for alopecia.

6. 1 measurable or evaluable lesion; = 1.8 cm diameter for cohort 1 (see Table 10); injection and biopsy accessible.

7. Age =18 years.

8. ECOG performance status (PS) 0-2.

9. Organ and marrow function as defined below:

Absolute granulocyte count = 1,500/mm^3 Platelets = 100,000/mm^3 Total bilirubin = 1.5x institutional ULN Creatinine = 2.0 mg/dL

10. Ability to understand and the willingness to sign a written informed consent document including permission for pre- and Days 1 and 2 post- injection biopsy and Day 8 injected lesion excision.

11. Negative pregnancy test.

Exclusion Criteria:

1. Surgery involving general anesthesia, chemotherapy, radiotherapy, or immunotherapy within 3 weeks prior to entering the study.

2. Patient must not have received any other investigational agents within 4 weeks prior to study entry.

3. Patients with known brain metastases unless treated with whole brain radiation and stable for >/= 2 months or treated with stereotactic radiotherapy only and stable for >/=1 month.

4. Short term (<30 days) concurrent systemic steroids =0.125 mg/kg prednisone per day (maximum 7.5 mg/day) and bronchodilators (inhaled steroids) are permitted; other steroid regimens and/or immunosuppressives are excluded.

5. Prior malignancy (excluding nonmelanoma carcinomas of the skin) unless in remission for >/= 2 years.

6. Kaposi's Sarcoma.

7. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

8. Patients who are pregnant or nursing.

9. Patients with known HIV.

10. Patients with chronic Hepatitis B and C infection.

11. Patients with uncontrolled diseases.

Related Conditions & MeSH terms

• Advanced Cancer
• Metastatic Cancer
• Neoplasm Metastasis
• Neoplasms
• Neoplasms, Second Primary
• Solid Tumors

Intervention

Biological:
• pbi-shRNA STMN1 LP
This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection. Patients will accrue in 4-patient escalation cohorts using a modified Fibronacci escalation schema at a starting intratumoral dose of 0.010 mg/kg of DNA through a dose of 0.053 mg/kg DNA intratumoral / single dose.

Locations

Country	Name	City	State
United States	Mary Crowley Cancer Research Centers	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Gradalis, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (3)

Phadke AP, Jay CM, Wang Z, Chen S, Liu S, Haddock C, Kumar P, Pappen BO, Rao DD, Templeton NS, Daniels EQ, Webb C, Monsma D, Scott S, Dylewski D, Frieboes HB, Brunicardi FC, Senzer N, Maples PB, Nemunaitis J, Tong AW. In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein. DNA Cell Biol. 2011 Sep;30(9):715-26. doi: 10.1089/dna.2011.1240. Epub 2011 May 25. — View Citation

Rana S, Maples PB, Senzer N, Nemunaitis J. Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther. 2008 Sep;8(9):1461-70. doi: 10.1586/14737140.8.9.1461. Review. — View Citation

Rao DD, Maples PB, Senzer N, Kumar P, Wang Z, Pappen BO, Yu Y, Haddock C, Jay C, Phadke AP, Chen S, Kuhn J, Dylewski D, Scott S, Monsma D, Webb C, Tong A, Shanahan D, Nemunaitis J. Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference. Cancer Gene Ther. 2010 Nov;17(11):780-91. doi: 10.1038/cgt.2010.35. Epub 2010 Jul 2. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the safety of intratumoral administration of pbi-shRNA™ STMN1 LP	To determine the safety of intratumoral administration of pbi-shRNA™ STMN1 LP in patients with superficial advanced and/or metastatic cancer who have no acceptable form of standard therapy.	1 month